22/11/2026, Sunday15:16

Menu

EDITION   :

TRTRENENARARFRFRRURUURUR

Notifications

You have no new notificationsHome
Turkish Aerospace Industries CEO Mehmet Demiroglu said Spain plans to purchase 15 additional Hurjet trainer aircraft after signing a deal for 30 of the Turkish-made supersonic jets, with deliveries to the European nation scheduled to begin in 2028.ASELSAN announced that its GOKALP Counter-UAV System successfully destroyed a target drone using a hit-to-kill interceptor during a live demonstration at the company's Ogulbey Technology Base, marking the entry of a fully mobile and cost-effective solution into Türkiye's autonomous air defense portfolio.President Recep Tayyip Erdogan on Friday criticized the existing global order and the United Nations, warning that binding international accords and judicial rulings are increasingly ignored while the UN system lacks legitimacy for failing to reflect the will of the global community.Foreign Minister Hakan Fidan said Thursday that Ankara has finalized preparations to submit the Mecca defense agreement to parliament for approval, stressing that the pact provides for mutual defense and does not authorize attacks or troop deployments to other countries.The Royal Swedish Academy of Sciences on Wednesday awarded the 2026 Nobel Prize in Chemistry to Henri Kagan and Kenso Soai for discoveries explaining how molecular asymmetry essential to life emerges through autocatalysis, resolving a century-old mystery about homochirality with significant implications for drug development.

Semaglutide heart benefits extend beyond weight loss, study finds

Elif Şanlı08:11, 23/10/2025, ThursdayG: Update: 08:12, 23/10/2025, Thursday
AA
File photo

New research published in The Lancet reveals the weight-loss drug semaglutide reduces heart attack and stroke risk independently of pounds lost. The study suggests the medication protects cardiovascular health through multiple biological mechanisms.

The diabetes and weight-loss medication semaglutide significantly lowers the risk of heart attacks and strokes, with new research indicating this benefit occurs independently of weight reduction. Published this week in the prestigious medical journal The Lancet, the findings suggest the drug, marketed as Wegovy, provides crucial cardiovascular protection through mechanisms beyond mere weight management.

Landmark International Research

The extensive study analyzed data from 17,604 participants across 41 countries, all aged 45 or older and classified as overweight or obese. In this randomized trial, half of the participants received a weekly semaglutide injection, while the other half were given a placebo. The research specifically tracked the occurrence of "major adverse cardiac events," a category encompassing heart-related deaths, non-fatal heart attacks, and strokes.

Cardiovascular Risk Reduction

An initial analysis of the trial data had already demonstrated that semaglutide reduced the risk of these major cardiac events by 20%. The new findings clarify that this protective effect was observed in patients regardless of the total amount of weight they lost during the treatment period. The benefits on cardiovascular outcomes were largely independent of weight loss observed in the first four months of therapy.

Mechanisms of Heart Protection

According to the researchers, the results point to multiple pathways through which semaglutide safeguards heart health, not solely through its known effect on body mass. While the total weight loss was not the primary mediator, the study did identify a significant correlation: approximately one-third of the drug's positive effect on cardiovascular events was linked to a reduction in waist circumference, a key indicator of abdominal fat.

Comments

Comments you share on our site are a valuable resource for other users. Please be respectful of different opinions and other users. Avoid using rude, aggressive, derogatory, or discriminatory language.